0001493152-24-015792.txt : 20240424 0001493152-24-015792.hdr.sgml : 20240424 20240424160529 ACCESSION NUMBER: 0001493152-24-015792 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240424 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240424 DATE AS OF CHANGE: 20240424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABEONA THERAPEUTICS INC. CENTRAL INDEX KEY: 0000318306 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 830221517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15771 FILM NUMBER: 24870551 BUSINESS ADDRESS: STREET 1: 6555 CARNEGIE AVE, 4TH FLOOR CITY: CLEVELAND STATE: OH ZIP: 44103 BUSINESS PHONE: 646-813-4701 MAIL ADDRESS: STREET 1: 6555 CARNEGIE AVE, 4TH FLOOR CITY: CLEVELAND STATE: OH ZIP: 44103 FORMER COMPANY: FORMER CONFORMED NAME: PLASMATECH BIOPHARMACEUTICALS INC DATE OF NAME CHANGE: 20140922 FORMER COMPANY: FORMER CONFORMED NAME: ACCESS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960209 FORMER COMPANY: FORMER CONFORMED NAME: CHEMEX PHARMACEUTICALS INC DATE OF NAME CHANGE: 19920703 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): April 24, 2024

ABEONA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Delaware

001-15771

83-0221517

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

6555 Carnegie Ave, 4th Floor

Cleveland, OH 44103

(Address of principal executive offices) (Zip Code)

(646) 813-4701
(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		ABEO		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The stockholders of Abeona Therapeutics Inc. (the “Company”) approved the Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (the “A&R Plan”) at the Company’s annual meeting of stockholders on April 24, 2024 (the “Annual Meeting”). The Company’s Board of Directors (the “Board”), upon the recommendation of the Compensation Committee of the Board, previously approved the A&R Plan on March 15, 2024, subject to stockholder approval. Additional information regarding the results of the Annual Meeting is set forth below in this Report under Item 5.07.

The A&R Plan increases the number of common shares, par value $0.01 per share, of the Company reserved for issuance under the plan by 1,500,000 shares, from 1,700,000 shares to 3,200,000 shares.

The foregoing description of the A&R Plan does not purport to be complete and is qualified in its entirety by the full text of the A&R Plan, which is attached as Appendix A to the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 19, 2024, and is incorporated by reference herein as Exhibit 10.1.

Item 5.07

Submission of Matters to a Vote of Security Holders.

The Annual Meeting was held virtually on April 24, 2024 at 9:00 a.m., Eastern Time. The following matters were acted upon:

Proposal 1. Election of Directors.

Leila Alland and Vishwas Seshadri were elected to serve as Class 2 directors of the Company until the 2027 annual meeting of stockholders and until their successors are elected and qualified. The results of the election of directors are as follows:

Nominee		Votes For		Votes Against		Abstentions		Broker Non-Votes
Leila Alland		8,985,852		958,122		12,938		5,093,839
Vishwas Seshadri		9,922,210		21,390		13,312		5,093,839

Proposal 2. Approval of an Increase in the Number of Shares Reserved for Issuance Under the A&R Plan.

A proposal to approve an increase in the number of shares reserved for issuance under the A&R Plan from 1,700,000 to 3,200,000 shares was approved based on the following votes:

Votes For		Votes Against		Abstentions		Broker Non-Votes
9,358,912		570,314		27,686		5,093,839

Proposal 3. Advisory Vote on Compensation of Named Executive Officers.

An advisory vote to approve the compensation of the Company’s named executive officers was approved by the following votes:

Votes For		Votes Against		Abstentions		Broker Non-Votes
9,529,727		402,844		24,341		5,093,839

Proposal 4. Ratification of the Appointment of Deloitte & Touche LLP as our Independent Registered Public Accounting Firm.

A proposal to ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024 was approved by the following votes:

Votes For		Votes Against		Abstentions		Broker Non-Votes
14,720,159		136,942		193,650		—

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
10.1		Amended and Restated Abeona Therapeutics Inc. 2023 Equity Incentive Plan (incorporated by reference to our Definitive Proxy Statement on Schedule 14A filed on March 19, 2024)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Abeona Therapeutics Inc.
	(Registrant)

	By:	/s/ Joseph Vazzano
	Name:	Joseph Vazzano
	Title:	Chief Financial Officer

Date: April 24, 2024

EX-101.SCH 2 abeo-20240424.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 abeo-20240424_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 abeo-20240424_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Apr. 24, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Apr. 24, 2024
Entity File Number	001-15771
Entity Registrant Name	ABEONA THERAPEUTICS INC.
Entity Central Index Key	0000318306
Entity Tax Identification Number	83-0221517
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	6555 Carnegie Ave
Entity Address, Address Line Two	4th Floor
Entity Address, City or Town	Cleveland
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	44103
City Area Code	(646)
Local Phone Number	813-4701
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ABEO
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abeonatherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports abeo-20240424.xsd abeo-20240424_lab.xml abeo-20240424_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "ABEO", "nsuri": "http://abeonatherapeutics.com/20240424", "dts": { "schema": { "local": [ "abeo-20240424.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "abeo-20240424_lab.xml" ] }, "presentationLink": { "local": [ "abeo-20240424_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://abeonatherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-24", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://abeonatherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001493152-24-015792-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-015792-xbrl.zip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end XML 16 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000318306 2024-04-24 2024-04-24 iso4217:USD shares iso4217:USD shares false 0000318306 8-K 2024-04-24 ABEONA THERAPEUTICS INC. DE 001-15771 83-0221517 6555 Carnegie Ave 4th Floor Cleveland OH 44103 (646) 813-4701 false false false false Common Stock, $0.01 par value ABEO NASDAQ false